RR No. 25-2018 exempts FDA-listed diabetes, cholesterol, and hypertension medicines from VAT on local sale starting January 1, 2019.
Starting January 1, 2019, businesses selling covered medicines for diabetes, high cholesterol, and hypertension must treat qualified sales as VAT-exempt, but only if the drug or medicine is included in the official VAT-exempt list identified and published by the Food and Drug Administration and posted through the BIR. RR No. 25-2018 matters immediately to pharmacies, drugstores, hospitals with pharmacy operations, medicine distributors, wholesalers, and manufacturers because the tax treatment depends not merely on the general use of the medicine, but on whether the specific drug is covered by the official list.
What RR No. 25-2018 Changed
RR No. 25-2018 implements Section 109(AA) of the National Internal Revenue Code of 1997, as amended by the TRAIN Law. The regulation provides the rules for the VAT exemption on the sale of drugs and medicines prescribed for the treatment and/or prevention of diabetes, high cholesterol, and hypertension.
The most important change is that, beginning January 1, 2019, sales of covered medicines by manufacturers, distributors, wholesalers, and retailers are exempt from VAT. This means that businesses in the medicine supply chain must identify which products qualify for VAT exemption and ensure that their invoicing and point-of-sale systems apply the correct VAT treatment.
The exemption is not a blanket exemption for all medicines or all health products. It is limited to drugs and medicines prescribed for diabetes, high cholesterol, and hypertension, and only those identified in the official list of VAT-exempt diabetes, high-cholesterol, and hypertension drugs. A product outside that list remains subject to VAT.
Who Is Affected by the VAT Exemption on Medicines
RR No. 25-2018 directly affects manufacturers, distributors, wholesalers, and retailers of drugs and medicines prescribed for diabetes, high cholesterol, and hypertension. In practical terms, this includes drug manufacturers, pharmaceutical importers and distributors, wholesale medicine suppliers, retail drugstores, pharmacy chains, hospital pharmacies, and other sellers that issue invoices for covered medicines.
Corporate accountants and CFOs of pharmaceutical and healthcare businesses should pay close attention because the regulation affects sales classification, invoicing, tax reporting, systems configuration, and internal product coding. A wrong classification can result in either improper VAT collection from customers or failure to impose VAT on a taxable sale.
Consumers and patients also benefit because covered medicines should be sold without VAT once the requirements of RR No. 25-2018 are met. However, the business seller remains responsible for determining whether the specific medicine is included in the official VAT-exempt list.
The Official List Controls Which Medicines Are VAT-Exempt
The regulation provides that the list of VAT-exempt diabetes, high-cholesterol, and hypertension drugs shall be identified and published by the Food and Drug Administration. The list is to be posted on the BIR website through a Revenue Memorandum Circular.
Any update to the list, including the registration of new or additional drugs and medicines, as well as the de-registration of drugs and medicines previously published by the FDA, shall likewise be posted on the BIR website. This is a critical compliance point. Businesses cannot rely only on a general product description, a supplier representation, or an internal medical classification. The controlling question is whether the drug is in the official VAT-exempt list.
The regulation expressly states that the sale of drugs not included in the list of VAT-exempt diabetes, high-cholesterol, and hypertension drugs published by the FDA shall be subject to VAT. For businesses, this means product master files, inventory systems, and accounting classifications must be updated whenever the official list changes.
Importation Remains Subject to VAT
RR No. 25-2018 makes an important distinction between the sale of covered drugs and medicines and their importation. While the sale by manufacturers, distributors, wholesalers, and retailers of covered drugs and medicines is VAT-exempt starting January 1, 2019, the importation of the same described drugs and medicines remains subject to VAT under Section 107 of the Tax Code, as amended.
This distinction is important for pharmaceutical importers and distributors. A medicine may later be sold as VAT-exempt if it is in the official list and qualifies under the regulation, but its importation is still subject to VAT. Businesses should therefore avoid assuming that a VAT-exempt local sale automatically means VAT-exempt importation.
Invoice Requirement: Indicate VAT-EXEMPT
RR No. 25-2018 imposes a specific invoicing requirement. In accordance with invoicing requirements, the word VAT-EXEMPT must be prominently indicated in the invoice issued for the sale of drugs and medicines prescribed for the treatment and prevention of diabetes, high cholesterol, and hypertension.
This requirement affects sales invoices, billing systems, cash register machines, point-of-sale software, and enterprise resource planning systems. Retail pharmacies and drugstore chains should ensure that the VAT-EXEMPT label appears clearly on invoices covering qualified medicines. Manufacturers, wholesalers, and distributors should also confirm that their commercial invoices properly reflect the VAT-exempt treatment for covered sales.
Businesses should not merely zero-rate the transaction or apply a manual discount without proper documentation. RR No. 25-2018 specifically requires the VAT-EXEMPT indication, so invoice format and system configuration are part of compliance.
Complaints and Enforcement
Complaints for non-compliance and violations of RR No. 25-2018 are to be forwarded for proper handling and dissemination to the concerned BIR office. Businesses selling medicines should therefore expect that customers, competitors, or other affected parties may raise compliance issues if VAT-exempt medicines are incorrectly charged with VAT or if taxable medicines are improperly treated as VAT-exempt.
For healthcare and pharmaceutical businesses, the safest approach is to keep a documented basis for VAT treatment. This includes maintaining a copy or record of the applicable official list, mapping covered products by brand, generic name, product code, or registration details, and preserving invoice samples showing the VAT-EXEMPT notation.
Penalties for Non-Compliance
RR No. 25-2018 provides that, notwithstanding other penalties that may be imposed for violations of specific regulations, any person who violates any provision of the regulation shall, in addition to the tax required to be paid, if any, upon conviction for each act or omission, be punished by a fine of not more than P1,000 or imprisonment of not more than six months, or both, pursuant to Section 275 of the Tax Code, as amended.
The penalty language is important because the exposure is not limited to correcting the VAT treatment. Where applicable, the tax required to be paid may still be collected, and a separate fine, imprisonment, or both may be imposed upon conviction for each act or omission.
Practical Compliance Steps for Businesses
First, review all medicines sold by the business and identify which products are prescribed for the treatment and/or prevention of diabetes, high cholesterol, and hypertension. Second, match those products against the official VAT-exempt list identified and published by the FDA and posted through the BIR. Third, classify products not included in the official list as VATable, even if they are generally associated with diabetes, cholesterol, or hypertension treatment.
Fourth, update accounting, inventory, invoicing, and point-of-sale systems so that qualified sales are treated as VAT-exempt starting January 1, 2019. Fifth, ensure that invoices for qualified medicines prominently indicate VAT-EXEMPT. Sixth, train pharmacists, cashiers, accounting personnel, sales teams, and compliance officers on the distinction between VAT-exempt sales and VATable importations.
Businesses should also periodically check for updates because the regulation recognizes that new or additional drugs may be registered and that previously listed drugs may be de-registered. A medicine that is VAT-exempt today may require re-checking if the official list changes. Conversely, newly registered medicines may become eligible once included in the official list and posted through the proper channel.
Why RR No. 25-2018 Matters to CFOs, Accountants, and Tax Managers
Common searches such as RR No. 25-2018 VAT exemption, VAT exempt medicines Philippines, diabetes medicine VAT exemption, hypertension drugs VAT exemption, and high cholesterol medicine VAT exemption all point to the same compliance issue: businesses must align tax treatment with the official list and invoice requirements.
For CFOs and tax managers, the risk is operational. The regulation requires product-level compliance. A business with thousands of SKUs cannot rely on general accounting assumptions. The finance team must coordinate with regulatory affairs, pharmacy operations, procurement, and IT to ensure the correct VAT treatment is applied to each covered medicine.
ASG Law Can Help with BIR and VAT Compliance
Ablola, Saribong & Gueco advises businesses on Philippine tax compliance, BIR issuances, VAT treatment, invoicing requirements, and regulatory implementation for healthcare, pharmaceutical, retail, and distribution operations. For companies affected by RR No. 25-2018, proper implementation requires more than knowing that certain medicines are VAT-exempt. It requires product review, invoice compliance, documentation, and defensible tax treatment.
For assistance with VAT compliance, BIR audits, invoicing issues, or tax treatment of medicines and healthcare products, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.